ReoPro GPIIb/IIIa inhibitor of platelets data

As reported at the meeting of the European Society of Cardiology in Stockholm, patients treated with the agent and who had angioplasty had a 74 percent reduced risk of a composite end point

Read the full 331 word article

How to gain access

Continue reading with a
two-week free trial.